PTGDR and congenital rubella syndrome: Currently, new treatment options are suggested in CRS cases: monoclonal antibodies, targets against sialic acid-binding Ig-like lectin 8 and thymic stromal lipoprotein (anti-Siglec-8 and anti-TSLP), PGD2 receptors antagonists.